The growth of Cann’s diverse product portfolio

Cann Group is constantly improving its range and diversity in its product portfolio for the benefit of its customers and patients.

In addition to improving upon existing genetics through an inhouse seed phenotyping and chemotyping program, Cann also partners with Agriculture Victoria to develop cross-bred genetics based on a world-leading phenotyping process. Already in 2023, an array of new cultivars have recently been sent from the Company’s R&D facility in Bundoora to its flagship Mildura facility for commercial cropping.

A recent extensive worldwide search has seen Cann complete a series of imports from leading international breeders. After putting each seed lot through a rigorous assessment phase, a shortlist was created for cultivation and subsequent patient assessment studies, before being offered on the commercial market.

Cann’s Product Innovation & Development Manager, James Yodgee, says the Company is improving the efficiency of these processes.

“There was a seed import earlier this year that we’re in the final stages of screening, with the first of two flowering rooms packed full of new genetics due to complete harvest this week,” Yodgee said.

“We’re planning to send six to eight new genetics up to Mildura every quarter now for approximately the next 12 months, with the goal of identifying and allocating two to four of those as new commercial strains that we can use to expand the flower portfolio of our existing customers or offer to new ones.

“This is a real space of growth for us moving forward. Compared to the last few years where our focus has been on getting the facility built and fully operational, we can now offer a real variety of exciting new products to our customers. Our genetics portfolio is rapidly expanding to cover an extensive range of terpene and cannabinoid profiles from genetics which have been popular in other countries but previously unseen in the Australian market. It’s also important to note that this is an ongoing process. Our goal is to strengthen our flower portfolio year after year, pushing the limits on yield, potency, aroma, terpene content and overall aesthetics.”

Previous
Previous

Consecutive months of record yield at Mildura

Next
Next

Cann receives $3.484 million R&D tax rebate